| Literature DB >> 32414033 |
Yu-Chi Lin1, Jue-Jun Lin1, Shu-Rong Chen1, Tsong-Long Hwang2,3,4, Shu-Yen Fang2, Michal Korinek2,3, Ching-Yeu Chen5, Yun-Sheng Lin6, Tung-Ying Wu6,7, Ming-Hong Yen8, Chih-Hsin Wang9, Yuan-Bin Cheng1,10,11.
Abstract
Plants of the genus Callicarpa are known to possess several medicinal effects. The constituents of the Taiwan endemic plant Callicarpa hypoleucophylla have never been studied. Therefore, C. hypoleucophylla was selected for our phytochemical investigation. Two new clerodane-type diterpenoids, named callihypolins A (1) and B (2), along with seven known compounds were isolated from the leaves and twigs of the Lamiaceae plant C. hypoleucophylla and then characterized. The structures of compounds 1 and 2 were elucidated by spectroscopic data analysis, specifically, two-dimension nuclear magnetic resonance (NMR). The anti-inflammatory activity of compounds 1-9 based on the suppression of superoxide anion generation and elastase release was evaluated. Among the isolates, compounds 2-4 showed anti-inflammatory activity (9.52-32.48% inhibition at the concentration 10 μm) by suppressing superoxide anion generation and elastase release. Our findings not only expand the description of the structural diversity of the compounds present in plants of the genus Callicarpa but also highlight the possibility of developing anti-inflammatory agents from Callicarpa endemic species.Entities:
Keywords: Callicarpa hypoleucophylla; anti-inflammatory activity.; clerodane diterpenoid
Mesh:
Substances:
Year: 2020 PMID: 32414033 PMCID: PMC7287842 DOI: 10.3390/molecules25102288
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–9 isolated from Callicarpa hypoleucophylla.
Figure 2COSY (bold bond), selected HMBC (arrow), and NOESY (left-right arrow) correlations of compound 1.
1H and 13C NMR Data of compounds 1 and 2 in CDCl3.
| 1 | 2 | |||
|---|---|---|---|---|
| Position | δH Mult. ( | δC, Type | δH Mult. ( | δC, Type |
| 1 | 2.56 (dd, 18.0, 14.2) | 34.4, CH2 | 1.46 (m) | 17.3, CH2 |
| 2.43 (dd, 18.0, 3.5) | 1.66 (m) | |||
| 2 | 199.0, C | 2.27 (m) | 27.4, CH2 | |
| 3 | 5.96 (s) | 126.6, CH | 6.85 (m) | 140.3, CH |
| 4 | 160.4, C | 141.2, C | ||
| 5 | 45.5, C | 37.5, C | ||
| 6 | 3.84 (dd, 12.6, 4.4) | 72.5, CH | 2.44 (m) | 35.7, CH2 |
| 1.14 (m) | ||||
| 7 | 1.70 (dt, 12.6, 4.4) | 36.1, CH2 | 1.46 (m) | 27.2, CH2 |
| 1.61 (m) | 1.42 (m) | |||
| 8 | 1.76 (m) | 34.5, CH | 1.50 (m) | 36.2, CH |
| 9 | 38.5, C | 38.7, C | ||
| 10 | 2.00 (dd, 14.2, 3.5) | 44.9, CH | 1.32 (d, 11.6) | 46.6, CH |
| 11 | 1.61 (m) | 34.8, CH2 | 1.50 (m) | 35.7, CH2 |
| 1.47 (m) | 1.66 (m) | |||
| 12 | 2.19 (m) | 18.7, CH2 | 2.20 (m) | 18.9, CH2 |
| 2.00 (tm, 13.0) | 2.03 (m) | |||
| 13 | 134.0, C | 139.0, C | ||
| 14 | 7.09 (quin, 1.7) | 143.9, CH | 6.76 (quin, 1.2) | 141.4, CH |
| 15 | 4.77 (dd, 3.9, 1.7) | 70.2, CH2 | 5.79 (brd, 1.2) | 101.6, CH |
| 16 | 174.0, C | 171.5, C | ||
| 17 | 0.90 (d, 6.8) | 15.3, CH3 | 0.81 (d, 6.2) | 15.9, CH3 |
| 18 | 169.8, C | 172.3, C | ||
| 19 | 1.33 (s) | 14.0, CH3 | 1.23 (s) | 20.5, CH3 |
| 20 | 0.84 (s) | 17.3, CH3 | 0.76 (s) | 18.2, CH3 |
| 1′ | 3.81 (s) | 52.8, CH3 | 3.94 (m) | 66.0, CH2 |
| 3.74 (m) | ||||
| 2′ | 1.27 (t, 7.1) | 15.0, CH3 | ||
1H and 13C-NMR were measured at 600 and 150 MHz. 1H and 13C-NMR were measured at 400 and 100 MHz.
Figure 3COSY (bold bond), selected HMBC (arrow), and NOESY (left-right arrow) correlations of compound 2.
Inhibitory effects of compounds 1–9 on superoxide anion generation and elastase release in formyl-methionyl-leucyl-phenylalanine (fMLF)/ cytochalasin (CB)-induced human neutrophils.
| Compound | Superoxide Anion | Elastase Release | ||
|---|---|---|---|---|
| Inh % | Inh % | |||
|
| 20.28 ± 5.98 | * | 8.26 ± 3.72 | |
|
| 32.19 ± 6.92 | ** | 17.55 ± 2.64 | *** |
|
| 31.19 ± 5.99 | ** | 12.15 ± 2.38 | *** |
|
| 32.88 ± 4.41 | *** | 13.57 ± 1.48 | *** |
|
| 23.65 ± 7.67 | * | 7.33 ± 1.56 | ** |
|
| 8.44 ± 6.40 | 10.50 ± 3.23 | * | |
|
| 7.93 ± 5.86 | 9.30 ± 2.91 | * | |
|
| 15.23 ± 6.37 | 11.80 ± 3.55 | * | |
|
| 18.80 ± 7.82 | 16.30 ± 3.74 | ** | |
|
| 89.00 ± 3.00 | *** | 22.79 ± 2.25 | *** |
Percentage of inhibition (Inh %) at 10 μM concentration. Results are presented as mean ± S.E.M. (n = 4–5); * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control (solvent). a Genistein served as a positive control.
Figure 4Compounds 1–9 do not cause LDH release in human neutrophils. Human neutrophils were incubated with DMSO (as a control) or compounds 1–9 (10 μM) for 15 min. Cytotoxicity was evaluated by LDH release. All data are presented as the means ± S.E.M. (n = 3).